More Optimism Around Sustainable Growth

Abbott Executive Vice President and Chief Financial Officer Brian Yoor explains how strategic shaping created a robust pipeline to fuel faster revenue growth.

NO IMAGE
Strategy and Strength | Mar. 15, 2019

Abbott's leadership has evolved the company prudently by investing in its own fast-growing medical technologies and by acquiring the right set of devices in the most promising areas of healthcare. The result: A global player with the richest pipeline of new offerings in its recent history, and investors are noticing.

The drivers behind the forecasted revenue growth of 6.5-7.5 percent this year include contributions from all Abbott businesses, said Brian Yoor, chief financial officer and executive vice president, at a Barclays investor conference. Abbott's FreeStyle Libre continuous glucose monitoring system, its Alinity diagnostics platforms and its fast-growing Mitraclip treatment to repair heart valves are just some of the technologies that are making a big impact.

"It's just an exciting time for Abbott, and it's exciting to have clear line of sight of where we're going and how we're getting there," Yoor said.